Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Lupus. 2021 Jul;30(8):1289-1299. doi: 10.1177/09612033211014570. Epub 2021 May 6.
Antiphosphatidylserine/prothrombin complex antibodies (aPS/PT) are risk factors for thrombosis, yet further validation of their clinical relevance in different ethnic groups is required. We investigated the performance of aPS/PT of IgA/G/M isotypes among Sudanese and Swedish systemic lupus erythematosus (SLE) patients.
Consecutive SLE patients/matched controls from Sudan (n = 91/102) and Sweden (n = 332/163) were included. All patients fulfilled the 1982 ACR SLE classification criteria. IgA/G/M of aPS/PT, anti-cardiolipin and anti-βglycoprotein I (anti-βGPI) were tested in both cohorts, and lupus anticoagulant (LA) also in the Swedish cohort. Clinical antiphospholipid syndrome-related events and atherosclerosis, measured as carotid plaques were assessed for associations. Univariate and multivariate analyses adjusting for cardiovascular risk factors were performed.
Sudanese SLE patients had higher levels of IgM aPS/PT, but using national cut-offs, the frequency of positivity was similar to Swedish patients for all isotypes. Among Swedish patients, all isotypes of aPS/PT associated with venous thromboembolism (VTE), while only IgA aPS/PT associated with arterial thrombosis (AT). aPS/PT antibodies associated strongly with LA and they were, independently, the best predictor for VTE. Double positivity for aPS/PT and anti-βGPI associated with higher VTE risk than the conventional triple positivity. Carotid plaques did not associate with any antiphospholipid antibody.
IgA aPS/PT associated with AT, and the association of IgG/M aPS/PT with VTE outperforms LA and criteria antiphospholipid antibodies in Swedish SLE patients. Furthermore, double positivity for aPS/PT and anti-βGPI performed better than conventional triple positivity. Future studies need to address if aPS/PT can replace LA, as this would simplify clinical procedures.
抗磷脂酰丝氨酸/凝血酶原复合物抗体(aPS/PT)是血栓形成的危险因素,但需要进一步验证其在不同种族人群中的临床相关性。我们研究了苏丹和瑞典系统性红斑狼疮(SLE)患者中 aPS/PT 的 IgA/G/M 同种型的表现。
纳入苏丹(n=91/102)和瑞典(n=332/163)连续的 SLE 患者/匹配对照。所有患者均符合 1982 年 ACR SLE 分类标准。苏丹和瑞典患者均检测了 IgA/G/M 的 aPS/PT、抗心磷脂和抗-β糖蛋白 I(抗-βGPI),瑞典患者还检测了狼疮抗凝物(LA)。评估了临床抗磷脂综合征相关事件和动脉粥样硬化(颈动脉斑块)的相关性。进行了调整心血管危险因素的单变量和多变量分析。
苏丹 SLE 患者 IgM aPS/PT 水平较高,但使用国家截断值,所有同种型的阳性率与瑞典患者相似。在瑞典患者中,所有 aPS/PT 同种型均与静脉血栓栓塞(VTE)相关,而仅 IgA aPS/PT 与动脉血栓形成(AT)相关。aPS/PT 抗体与 LA 密切相关,并且是 VTE 的最佳预测指标。aPS/PT 和抗-βGPI 的双重阳性与比传统三联阳性更高的 VTE 风险相关。颈动脉斑块与任何抗磷脂抗体均无关。
IgA aPS/PT 与 AT 相关,并且 IgG/M aPS/PT 与 VTE 的相关性优于 LA 和传统的抗磷脂抗体在瑞典 SLE 患者中。此外,aPS/PT 和抗-βGPI 的双重阳性比传统的三联阳性表现更好。未来的研究需要确定 aPS/PT 是否可以替代 LA,因为这将简化临床程序。